Effects of aspirin and clopidogrel on the risk of upper gastrointestinal bleeding in patients with cardiovascular and cerebrovascular diseases
Objective To investigate the effects of aspirin and clopidogrel on the risk of upper gastrointestinal bleeding in patients with cardiovascular and cerebrovascular diseases. Methods 116 cases of patients with upper gastrointestinal bleeding and cardiovascular disease as research subjects. 86 cases of patients used antiplatelet drugs (drug group), 30 cases didn't use antiplatelet drugs (non-drug group). In the drug group, 30 patients with aspirin alone (group A), 24 patients with clopidogrel alone (group B) and 32 patients with aspirin and clopidogrel (group C) . Compared the upper gastrointestinal bleeding in each group of patients. Results The incidence of abdominal pain in the drug group was significantly lower than non-drug group (P<0.05). However, there was no significant difference in the incidence of bloating, nausea, vomiting, acid reflux compared with non - drug group. There were no significant differences in the endoscopic manifestations of gastrointestinal bleeding between the drug group and the non-drug group. The incidence of severe gastrointestinal bleeding in the drug group was 47.67%, significantly higher than that in the non-drug group (26.67%)(P<0.05). A, B, C three groups of patients with severe gastrointestinal bleeding rate and bleeding patterns were no significant difference. There was no significant difference in the total effective rate of gastrointestinal bleeding between the drug group and the non-drug group. Conclusion Antiplatelet drugs may increase the risk of upper gastrointestinal bleeding in patients with cardiovascular and cerebrovascular diseases, but aspirin and clopidogrel alone or in combination had no significant effect on the degree of gastrointestinal bleeding.
upper gastrointestinal bleedingclopidogrelaspirincardiovascular and cerebrovascular diseases
NETL
NSTL
万方数据
维普
